|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR:A systematic literature review显示文摘AIM:To review literature on efficacy and safety of octreotide-long-acting repeatable(LAR)used at doses higher than the Food and Drug Administration(FDA)-approved 30 mg/mo for treatment of neuroendocrine tumors(NETs).METHODS:We searched Pub Med and Cochrane Library from 1998-2012,5 conferences(American Society of Clinical Oncology,Endocrine Society,European Neuroendocrine Tumor Society,European Society for Medical Oncology,North American Neuroendocrine Tumor Society)from 2000-2013 using Me SH and keyterms including neuroendocrine tumors,carcinoid tumor,carcinoma,neuroendocrine,and octreotide.Bibliographies of accepted articles were also searched.Two reviewers reviewed titles,abstracts,and full-length articles.Studies that reported data on efficacy and safety of≥30 mg/mo octreotide-LAR for NETs in human subjects,published in any language were included in the review.RESULTS:The search identified 1086 publications,of which 238 underwent full-text review(20 were translated into English);17 were included in the review.Studies varied in designs,subjects,octreotide-LAR regimens,and definition of outcomes.Eleven studies reported use of higher doses to control symptoms and tumor progression,although symptom severity and formal quality-of-life analysis were not quantitatively measured.Ten studies reported efficacy,describing 260 subjects with doses ranging from 40 mg/mo or 30 mg/3 wk up to 120 mg/mo.Eight studies reported expert clinical opinion that supported dose escalation of octreotide-LAR up to 60 mg/mo for symptom control and suggested increased doses may be effective at preventing tumor progression.Eight studies reported safety;there was no evidence of increased toxicity associated with doses of octreotide-LAR>30 mg/mo.CONCLUSION:As reported in this review,octreotide-LAR at doses>30 mg/mo is being prescribed for symptom and tumor control in NET patients.Furthermore,expert clinical opinion provided support for escalation of somatostatin analogs for refractory hormonal symptoms. | Michael S Broder David Beenhouwer Jonathan R Strosberg Maureen P Neary Dasha Cherepanov | 2015 | World Journal of Gastroenterology2015，21，6： | 8 |
| 2 | Bacillus thuringiensis: Biology, Ecology and Safety显示文摘 | Travis R G Maureen O | 2002 | Biocontrol Biosecurity Agresearch New Zealand2002，11，： | 2 |
| 3 | Acute ischaemic stroke interventions: large vessel occlusion and beyond显示文摘Care for acute ischaemic stroke is one of the most rapidly evolving fields due to the robust outcomes achieved by mechanical thrombectomy.Large vessel occlusion(LVO)accounts for up to 38%of acute ischaemic stroke and comes with devastating outcomes for patients,families and society in the pre-intervention era.A paradigm shift and a breakthrough brought mechanical thrombectomy back into the spotlight for acute ischaemic stroke;this was because five randomised controlled trials from several countries concluded that mechanical thrombectomy for acute stroke offered overwhelming benefits.This review article will present a comprehensive overview of LVO management,techniques and devices used,and the future of stroke therapy.In addition,we review our institution experience of mechanical thrombectomy for posterior and distal circulation occlusion. | Ahmad Sweid Batoul Hammoud Sunidhi Ramesh Daniella Wong Tyler D Alexander Joshua Harrison Weinberg Maureen Deprince Jaime Dougherty Dimitri Jean-Mickael Maamari Stavropoula Tjoumakaris Hekmat Zarzour Michael R Gooch Nabeel Herial Victor Romo David M Hasan Robert H Rosenwasser Pascal Jabbour | 2020 | Stroke & Vascular Neurology2020，5，1： | 2 |
| 4 | A randomized comparison of oral and intravaginal misoprostol for labor induction显示文摘 | Deborah A Wing Maureen R Park Richard H Paul | 2000 | Obstetrics & Gynecology2000，，6： | 2 |
| 5 | Levels of Expression of P-Selectin, E-Selectin, and Intercellular Adhesion Molecule-1 in Coronary Atherectomy Specimens from Patients With Stable and Unstable Angina Pectoris显示文摘 | Alan N Tenaglia MD Andrew J Buda MD Robert G Wilkins MD Michael K Barron MD Paul R Jeffords BS Khoa Vo BS Maureen O Jordan BS Barry A Kusnick MD David J Lefer PhD | 1997 | The American Journal of Cardiology1997，，6： | 1 |
| 6 | Effect of textile properties in evalu- ating a directional shading fabric 显示文摘 | MAUREEN M G BRUCE D H ARDIS M R | 1997 | Textile Research Journal1997，67，4： | 1 |
| 7 | smith, Determinants of Sport Commitment Among Junior Tennis Players: Enjoyment as a Mediating Variable显示文摘 | Maureen R Weiss Lissa A Kimmel Alan L | 2001 | Pediatric Exercise Science2001，13，： | 1 |
| 8 | Gamma linolenic acid attenuates cardiovascuar responses to stress in borderline hypertensive rats 显示文摘 | David E M Maureen R S | 1985 | Lipids1985，20，9： | 1 |
| 9 | Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: the crystal structure provides insights into the mode of unwinding显示文摘 | Joseph L Kim Kurt A Morgenstern James P Griffith Maureen D Dwyer John A Thomson Mark A Murcko Chao Lin Paul R Caron | 1998 | Structure1998，，1： | 1 |
| 10 | Clinical Association with Urinary GlycosamiNoglyc-ans and Urolithiasis 显示文摘 | Erdal Erturk Maureen Kiernan Susan R Schoen | 2002 | Adult Urology2002，59，4： | 1 |
| 11 | Shipping charges and shipping charge skepticism: implications for direct marketers pricing format 显示文摘 | Schindler R M Maureen M Nada N B | 2005 | Journal of Interactive Marketing2005，，1： | 1 |
| 12 | Children' s self-perceptions and sources of physical competence information: A cluster analysis显示文摘 | Weiss Maureen R Ebbeck Vicki Horn Thelma S | 1997 | Journal of Sport & Exercise Psychology1997，19，1： | 1 |
| 13 | A strain of the fungus metarhizium anisopliae for controlling subterranean termite 显示文摘 | Wright Maureen S Raiina Ashok K Lax Alan R | 2005 | J Econ Entomol2005，98，5： | 1 |
| 14 | 早期乳腺癌最佳辅助化疗方案与人类表皮生长因子受体2阳性乳腺癌辅助靶向治疗选择:依据 ASCO 对 CCO临床实践指南的改编显示文摘目的研究加拿大安大略癌症治疗中心(CCO)关于早期乳腺癌最佳辅助化疗方案,包括人类表皮生长因子受体2(HER2)阳性乳腺癌辅助靶向治疗方案,并对其进行改编。方法按照美国临床肿瘤协会(ASCO)对其他组织临床实践指南改编的策略和程序,对CCO临床实践指南的严谨性与内容适用性进行回顾。结果基于对CCO临床实践指南内容的回顾,ASCO小组认为,CCO临床实践指南在整体上清晰全面,以最确切的科学证据为基础,为患者提供可接受的治疗选项。推荐关于辅助化疗方案的决定,应考虑到基线复发风险、毒性、利益可能性和宿主因素(如合并症)。对于高风险HER2阴性的身体状况良好的人群,蒽环类和紫杉烷治疗方案是标准治疗方案。4个周期的多西他赛和环磷酰胺治疗方案是可接受的非蒽环类治疗方案。对于高风险HER2阳性患者,推荐蒽环类与紫杉烷序贯疗法联合曲妥单抗或多西他赛、卡铂、曲妥单抗进行6个周期的治疗。对于低风险、非淋巴结转移、HER2阳性人群,推荐每周一次的紫杉醇和曲妥单抗连续进行12个周期的替代治疗。曲妥单抗应持续使用1年。不应采用铂复合盐对三阴性人群进行常规的辅助管理,除非出现有效的生存数据加以支持。 | Neelima Denduluri Mark R Somerfield Andrea Eisen Jamie N Holloway Arti Hurria Tari A King Gary H Lyman Ann H Partridge Melinda L Telli Maureen E Trudeau Antonio C Wolff 本刊编辑部 | 2016 | 中国全科医学2016，19，18： | 1 |
| 15 | Child sexual abuse:from prevention to selfprotection显示文摘 | Maureen C Kenny Vjolca Capri Reena R ThakkarKolar | 2008 | Child Abuse Review2008，17，： | 1 |
| 16 | Younger women with breast carcinoma have a poorer prognosis the Han older women 显示文摘 | Maureen C Helena R Kirby B | 1996 | Caneer1996，77，3： | 1 |
| 17 | Flucon_ azole therapy in transplant recipients receiving FK506 显示文摘 | Manoz R Maureen M Venkatramanan R | 1994 | Transplantation1994，57，： | 1 |
| 18 | Nasogastric feeding for stroke patients : practice and education 显示文摘 | Catherine M Anne R Maureen M | 2015 | Br J Nurs2015，24，6： | 1 |
| 19 | An Innovative Approach to the Care of Patients on Phase Ⅰ and Phase Ⅱ Clinical Trials:The Role of the Experimental Therapeutics Nurse显示文摘 | Claire C Maureen R Anne H | 2005 | Pediatric Oncology Nursing2005，22，6： | 1 |
| 20 | Statistical significance of freeze-thaw related factors on cumulative damage to flexible pavements 显示文摘 | Kestler Maureen A Berg Richard L Bigl Susan R | 2011 | Trans- portation Research Record2011，2232，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员